DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+37.19%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$859M
AUM Growth
+$859M
(+14%)
Cap. Flow
+$123M
Cap. Flow
% of AUM
14.33%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
17
New
5
Increased
1
Reduced
3
Closed
8
Top Buys
| 1 |
Cytokinetics
CYTK
|
$246M |
| 2 |
Insmed
INSM
|
$237M |
| 3 |
Geron
GERN
|
$106M |
| 4 |
Corbus Pharmaceuticals
CRBP
|
$14.3M |
| 5 |
Avidity Biosciences
RNA
|
$8.11M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$108M |
| 2 |
Biohaven
BHVN
|
$80.8M |
| 3 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$78.6M |
| 4 |
Beam Therapeutics
BEAM
|
$70M |
| 5 |
Apogee Therapeutics
APGE
|
$55.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$4.23B
| $246M | 28.63% | +4,575,558 | New | +$246M |
|
|
2
Insmed
INSM
$28.8B
| $237M | 27.58% | +3,541,095 | New | +$237M |
|
3
Vaxcyte
PCVX
$4B
| $164M | 19.07% | 2,080,946 -669,858 | -24% | -$52.8M |
|
|
4
Geron
GERN
$893M
| $106M | 12.35% | +23,915,480 | New | +$106M |
|
5
Keros Therapeutics
KROS
$618M
| $68.8M | 8% | 1,525,902 +89,952 | +6% | +$4.05M |
|
|
6
Corbus Pharmaceuticals
CRBP
$115M
| $14.3M | 1.66% | +325,140 | New | +$14.3M |
|
7
Spyre Therapeutics
SYRE
$996M
| $10.3M | 1.19% | 452,040 -21,160 | -4% | -$481K |
|
|
8
Avidity Biosciences
RNA
$5.99B
| $8.11M | 0.94% | +200,000 | New | +$8.11M |
|
|
ELEV
9
DELISTED
Elevation Oncology
ELEV
| $4.81M | 0.56% | 1,916,290 -416,638 | -18% | -$1.05M |
|
|
10
Apogee Therapeutics
APGE
$2.17B
| – | – | -832,198 | Closed | -$55.3M |
|
|
11
Beam Therapeutics
BEAM
$1.66B
| – | – | -2,119,598 | Closed | -$70M |
|
|
12
Biohaven
BHVN
$1.63B
| – | – | -1,476,974 | Closed | -$80.8M |
|
13
Merck
MRK
$210B
| – | – | -79,600 | Closed | -$10.5M |
|
|
14
Nuvalent
NUVL
$5.52B
| – | – | -1,436,964 | Closed | -$108M |
|
15
Tourmaline Bio
TRML
$601M
| – | – | -465,000 | Closed | -$10.6M |
|
16
Xencor
XNCR
$580M
| – | – | -1,109,650 | Closed | -$24.6M |
|
|
ALPN
17
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – | -1,982,016 | Closed | -$78.6M |
|